Last reviewed · How we verify
Ceftolozane / Tazobactam Injection
Ceftolozane inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, together providing broad-spectrum coverage against resistant gram-negative bacteria.
Ceftolozane inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, together providing broad-spectrum coverage against resistant gram-negative bacteria. Used for Complicated urinary tract infections (cUTI) including pyelonephritis, Complicated intra-abdominal infections (cIAI), Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
At a glance
| Generic name | Ceftolozane / Tazobactam Injection |
|---|---|
| Sponsor | Weill Medical College of Cornell University |
| Drug class | Beta-lactam / beta-lactamase inhibitor combination |
| Target | Bacterial penicillin-binding proteins; beta-lactamase enzymes |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ceftolozane is a fifth-generation cephalosporin that binds to penicillin-binding proteins and disrupts peptidoglycan cross-linking in the bacterial cell wall. Tazobactam is a beta-lactamase inhibitor that protects ceftolozane from degradation by bacterial beta-lactamase enzymes, particularly those produced by Pseudomonas aeruginosa and Enterobacteriaceae. This combination extends the spectrum of activity against multidrug-resistant gram-negative pathogens.
Approved indications
- Complicated urinary tract infections (cUTI) including pyelonephritis
- Complicated intra-abdominal infections (cIAI)
- Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
Common side effects
- Diarrhea
- Nausea
- Headache
- Vomiting
- Fever
- Hypersensitivity reactions
Key clinical trials
- Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation (PHASE4)
- Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: